Company / R&D per Share
Vericel R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$0.56
FY2025
5-year range
$0.28 / $0.66
FY2021-FY2025
Trend
+7.1%
vs FY2024
Sector context
#172 of 208
Health Care
What the data says
Vericel's r&d per share of $0.56 is lower than 83% of companies in the Health Care sector (FY2025). R&D per Share has increased for 3 consecutive years, from $0.28 in FY2022 to $0.56 in FY2025.
Based on SEC 10-K filings.
0.56 in FY2025 with a 5-year CAGR of +12.9%.
Improved from $0.45 to $0.56 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +26.0%
- 5-Year CAGR
- +12.9%
- 10-Year CAGR
- -
Sector benchmark
Bottom 17% in Health CareTop 83% of 208This company $0.56 Sector average $28.82
▼
-98.1% below sector average
Key checks
Key Insights
- Vericel's r&d per share has grown for 3 consecutive years.
- In FY2025, r&d per share increased 7.1% year-over-year.
- Ranks #172 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2016.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.56 | +7.1% |
| FY2024 | $0.52 | +16.4% |
| FY2023 | $0.45 | +60.3% |
| FY2022 | $0.28 | -58.1% |
| FY2021 | $0.66 | +118.9% |
| FY2020 | $0.30 | +2.0% |
| FY2019 | $0.30 | -30.4% |
| FY2018 | $0.43 | -28.7% |
| FY2017 | $0.60 | -33.1% |
| FY2016 | $0.89 | +40.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026